Dr Reddy's Labs receives USFDA EIR for Srikakulam facility
Advertisement
New Delhi: Drugmaker, Dr Reddy's Labs, has recently announced that the Company has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the formulations manufacturing facility (FTO 11) in Srikakulam, Andhra Pradesh.
"The Agency has concluded that the inspection is "closed" under 21 C.F.R.20.64(d)(3)," the company stated in a BSE filing.
Medical Dialogues team had earlier reported that the USFDA had issued a Form 483 with two observations after a PreApproval Inspection (PAI) at its manufacturing facility.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.